Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE OTCMKTS:CUBT NASDAQ:EGRX NASDAQ:LTRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.45-4.1%$5.02$1.00▼$7.00$41.13M0.411,867 shs41,887 shsCUBTCurative Biotechnology$0.01+14.1%$0.01$0.00▼$0.03$7.90M0.3480,881 shs356,699 shsEGRXEagle Pharmaceuticals$3.73+16.0%$3.35$1.50▼$3.87$48.38M0.836,057 shs1,684 shsLTRNLantern Pharma$4.10+7.6%$4.24$2.55▼$6.12$41.15M1.4771,295 shs718,522 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-4.92%-10.25%-10.94%+7.16%+268.25%CUBTCurative Biotechnology-21.21%-16.13%-23.53%-24.27%-41.35%EGRXEagle Pharmaceuticals+16.04%+16.04%+16.41%+58.51%-13.57%LTRNLantern Pharma-0.52%-6.16%-16.63%+20.95%-5.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.45-4.1%$5.02$1.00▼$7.00$41.13M0.411,867 shs41,887 shsCUBTCurative Biotechnology$0.01+14.1%$0.01$0.00▼$0.03$7.90M0.3480,881 shs356,699 shsEGRXEagle Pharmaceuticals$3.73+16.0%$3.35$1.50▼$3.87$48.38M0.836,057 shs1,684 shsLTRNLantern Pharma$4.10+7.6%$4.24$2.55▼$6.12$41.15M1.4771,295 shs718,522 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-4.92%-10.25%-10.94%+7.16%+268.25%CUBTCurative Biotechnology-21.21%-16.13%-23.53%-24.27%-41.35%EGRXEagle Pharmaceuticals+16.04%+16.04%+16.41%+58.51%-13.57%LTRNLantern Pharma-0.52%-6.16%-16.63%+20.95%-5.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00169.66% UpsideCUBTCurative Biotechnology 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/ALTRNLantern Pharma 3.00Buy$25.00509.76% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals$257.55M0.19$9.31 per share0.40N/A∞LTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/A0.00∞N/AN/AN/AN/AN/ACUBTCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ALTRNLantern Pharma-$20.78M-$1.78N/AN/AN/AN/A-99.89%-81.58%11/6/2025 (Estimated)Latest CUBT, ATHE, LTRN, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LTRNLantern Pharma-$0.53-$0.40+$0.13-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.9812.98CUBTCurative BiotechnologyN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/ALTRNLantern PharmaN/A3.523.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%CUBTCurative BiotechnologyN/AEGRXEagle Pharmaceuticals85.36%LTRNLantern Pharma28.62%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%CUBTCurative BiotechnologyN/AEGRXEagle Pharmaceuticals28.90%LTRNLantern Pharma8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableCUBTCurative Biotechnology41.01 billionN/ANot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataLTRNLantern Pharma2010.80 million9.88 millionOptionableCUBT, ATHE, LTRN, and EGRX HeadlinesRecent News About These CompaniesLantern Pharma announces LP-184 trial met all primary endpoints4 hours ago | msn.comLantern Pharma trading halted, news pendingSeptember 16 at 12:06 PM | msn.comLantern Pharma stock climbs after LP-184 cancer drug hits trial endpointsSeptember 16 at 12:06 PM | in.investing.comLantern Pharma Shares Soar as LP-184 Cancer Drug Hits Key Trial GoalsSeptember 16 at 12:06 PM | msn.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)September 10, 2025 | globenewswire.comLantern Pharma announces completion of Type C meeting with FDASeptember 3, 2025 | msn.comLantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer TrialSeptember 3, 2025 | businesswire.comLantern Pharma Reports Q2 2025 Earnings and Strategic ProgressAugust 22, 2025 | msn.comRedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26August 19, 2025 | miamiherald.comMRedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26August 19, 2025 | finanznachrichten.deLantern Pharma Narrows Loss in Q2August 14, 2025 | aol.comALantern Pharma Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 13, 2025 | businesswire.comLantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% AccuracyAugust 7, 2025 | theglobeandmail.comLantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™August 4, 2025 | businesswire.comLantern Pharma (LTRN) Gets a Buy from Lake StreetAugust 4, 2025 | theglobeandmail.comLantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in JapanJuly 31, 2025 | theglobeandmail.comLantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300July 31, 2025 | businesswire.comLantern Pharma Appoints Dr. Schalop to BoardJuly 30, 2025 | msn.comLantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision OncologyJuly 28, 2025 | theglobeandmail.comLantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsJuly 28, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Not Just NVDA: 3 Semiconductor Stocks Struggling This QuarterBy Dan Schmidt | September 12, 2025CUBT, ATHE, LTRN, and EGRX Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.45 -0.19 (-4.09%) Closing price 04:00 PM EasternExtended Trading$4.44 0.00 (-0.11%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Curative Biotechnology OTCMKTS:CUBT$0.0089 +0.00 (+14.10%) As of 11:08 AM EasternCurative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.Eagle Pharmaceuticals NASDAQ:EGRX$3.72 +0.52 (+16.04%) As of 09/15/2025 12:20 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Lantern Pharma NASDAQ:LTRN$4.10 +0.29 (+7.61%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.11 (-2.56%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
